Although most previous studies showed that PCT was a validated biomarker of infections in patients with liver disease, there was considerable discrepancy in the optimal cut-offs.[13–16] This prominent variation could be explained by differences in methodology (such as different inclusion and exclusion criteria, different baselines of liver function, different etiologies and different races), the severity of infectious episodes and the relatively small number of cases involved. The gene discussed is CALCA; the disease is liver disorder.